. Author manuscript; available in PMC: 2016 May 25.

Published in final edited form as: J Nat Prod. 2015 May 22;78(6):1271–1276. doi: 10.1021/acs.jnatprod.5b00065

Table 4.

Behavioral Effects of the Intraperitoneal Administration of Selected Cannabinoids in a Mouse Tetrad Assay

treatment group (mg/kg)	locomotor activity	catalepsy latency (s)	tail-flick latency (% MPE)	hot-plate latency (% MPE)	decrease in rectal temperature (°C)
vehicle	2091 ± 209.3	2.1 ± 0.60	0.84 ± 3.58	8.32 ± 2.20	0.58 ± 0.26
Δ⁹-THC
10	190.9 ± 33.8^c	14.4 ± 4.16	6.52 ± 2.00	29.04 ± 5.37^c	2.05 ± 0.25
20	276.2 ± 52.6^c	47.9 ± 20.04^b	42.21 ± 17.04^b	46.85 ± 9.08^c	4.25 ± 0.78^c
40	194.0 ± 49.2^c	37.7 ± 14.64^a	51.96 ± 13.22^c	38.18 ± 4.05^c	4.80 ± 0.28^c
Δ⁸-THC
5	1480 ± 184.3	1.6 ± 0.60	8.01 ± 5.88	12.82 ± 1.84	0.12 ± 0.09
20	377.4 ± 169.7^c	5.3 ± 2.68	5.97 ± 1.63	16.98 ± 3.53	1.96 ± 0.37^a
compound 1
20	908.90 ± 245.10	1.50 ± 0.33	5.01 ± 3.59	4.95 ± 1.89	0.58 ± 0.18
compound 2
10	1617 ± 364.50	1.143 ± 0.14	0.13 ± 3.50	11.83 ± 3.16	0.49 ± 0.49
20	1148 ± 242.60^a	1.43 ± 0.29	1.62 ± 3.92	2.04 ± 2.48	0.50 ± 0.31
40	777.40 ± 185.10^b	11.43 ± 3.92	12.69 ± 6.62	11.79 ± 2.48	0.91 ± 0.18
compound 3
5	318.1 ± 96.29^c	22.0 ± 12	37.40 ± 12.62^a	21.04 ± 6.27	2.46 ± 0.52^b
10	288.3 ± 98.7^c	23.9 ± 6.71	31.46 ± 12.64	56.33 ± 8.61^c	3.21 ± 0.3^c
20	301.9 ± 62.9^c	51.1 ± 18.59^a	90.16 ± 6.16^c	47.63 ± 7.80^c	5.38 ± 0.38^c
compound 4
10	3045 ± 266.3^a	1.4 ± 0.31	2.20 ± 1.16	6.819 ± 3.18	0.47 ± 0.18
40	2537 ± 316.1	13.70 ± 4.55	69.95 ± 14.02^c	55.65 ± 7.74^c	5.32 ± 0.29^c
compound 6
5	213.40 ± 49.77^c	23.80 ± 10.55^a	16.25 ± 7.08	36.98 ± 8.87^a	3.75 ± 0.42^c
10	291.20 ± 69.89^c	8.80 ± 3.39	82.71 ± 11.31^c	35.89 ± 7.56^a	3.11 ± 0.25^c
20	380.30 ± 109.70^c	27.50 ± 7.83^a	50.37 ± 15.99^b	49.39 ± 13.81^b	4.58 ± 0.65^c
compound 8
20	1892 ± 121.20	2.25 ± 1.25	2.98 ± 2.36	2.40 ± 6.71	0.45 ± 0.20

< 0.05.

< 0.01.

< 0.001 versus vehicle (Dunnett’s posthoc test).